Drug Trial Radar · NCT04321252
Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Jul 22, 2020
Primary completion
Nov 10, 2020
Study completion Nov 10, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- Wellcome Trust
- First posted
- Mar 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a randomized, subject and investigator-blinded, placebo-controlled, single and multiple ascending intravenous (iv) dose study in healthy subjects to assess the safety and tolerability of KAE609 given in the vein.
Conditions
- Malaria
Interventions
KAE609Drug
* iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1) * iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)
PlaceboDrug
matching placeo for iv administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With On-Treatments Adverse Events, Serious Adverse Events, and DeathsTime frame: From study treatment start date till 30 days safety follow-up, assessed for up to 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Antwerp, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.